The results of our study showed that ANXA1, A10 and A13 can be considered as good immunohis-tochemical biomarker candidates to differentiate CCA and PDA, however they should be interpreted in a panel in conjunction with the clinical and imaging findings. This evidence concerns the gene ANXA1 and Patent ductus arteriosus.